MicroRNA profiling of rats with ochratoxin A nephrotoxicity

BMC Genomics

Volumn 15, Issue 1, 2014, Pages

  Dai, Qiu ^a   Zhao, Jue ^a   Qi, Xiaozhe ^a   Xu, Wentao ^a   He, Xiaoyun ^a   Guo, Mingzhang ^a   Dweep, Harsh ^b   Cheng, Wen Hsing ^c   Luo, Yunbo ^a   Xia, Kai ^a   Gretz, Norbert ^b   Huang, Kunlun ^a  

^a CHINA AGRICULTURAL UNIVERSITY   (China)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c MISSISSIPPI STATE UNIVERSITY   (United States)

Author keywords

High throughput sequencing; miRNA biogenesis; miRNA expression; Nephrotoxicity; Ochratoxin A

Indexed keywords

ASPARTATE AMINOTRANSFERASE; DICER; DROSHA PROTEIN; HIGH DENSITY LIPOPROTEIN; LACTATE DEHYDROGENASE; MICRORNA; MICRORNA 129; MICRORNA 130A; MICRORNA 130B; MICRORNA 141; MICRORNA 218B; MICRORNA 3588; MITOGEN ACTIVATED PROTEIN KINASE; NITROGEN; NUCLEAR PROTEIN; OCHRATOXIN; UNCLASSIFIED DRUG; UREA;

ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BIOINFORMATICS; BODY WEIGHT; CONTROLLED STUDY; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE REPRESSION; GENE TARGETING; HIGH THROUGHPUT SEQUENCING; KIDNEY; LACTATE DEHYDROGENASE BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; NEPHROTOXICITY; NONHUMAN; ORGAN WEIGHT; RAT; RNA ANALYSIS; SIGNAL TRANSDUCTION; UREA NITROGEN BLOOD LEVEL; ANIMAL; DRUG EFFECTS; GENETICS; METABOLISM; POLYMERASE CHAIN REACTION; TOXICITY; VALIDATION STUDY;

RATTUS;

ANIMALS; GENE EXPRESSION PROFILING; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; KIDNEY; MAP KINASE SIGNALING SYSTEM; MICRORNAS; OCHRATOXINS; POLYMERASE CHAIN REACTION; RATS;

EID: 84900419033     PISSN: None     EISSN: 14712164     Source Type: Journal    
DOI: 10.1186/1471-2164-15-333     Document Type: Article

References (38)

1. van der Merwe KJ, Steyn PS, Fourie L, Scott DB, Theron JJ. Ochratoxin A, a toxic metabolite produced by Aspergillus ochraceus Wilh. Nature 1965, 205(976):1112-1113.
2. Bhatnagar D, Yu J, Ehrlich KC. Toxins of filamentous fungi. Chem Immunol 2002, 81:167-206.
3. Pfohl-Leszkowicz A, Manderville RA. Ochratoxin A: an overview on toxicity and carcinogenicity in animals and humans. Mol Nutr Food Res 2007, 51(1):61-99. 10.1002/mnfr.200600137, 17195275.
4. Marin-Kuan M, Nestler S, Verguet C, Bezencon C, Piguet D, Delatour T, Mantle P, Cavin C, Schilter B. MAPK-ERK activation in kidney of male rats chronically fed ochratoxin A at a dose causing a significant incidence of renal carcinoma. Toxicol Appl Pharm 2007, 224(2):174-181.
5. Izzotti A, Calin GA, Arrigo P, Steele VE, Croce CM, De Flora S. Downregulation of microRNA expression in the lungs of rats exposed to cigarette smoke. FASEB J 2009, 23(3):806-812. 10.1096/fj.08-121384, 2653990, 18952709.
6. Du Y, Xu Y, Ding L, Yao H, Yu H, Zhou T, Si J. Down-regulation of miR-141 in gastric cancer and its involvement in cell growth. J Gastroenterol 2009, 44(6):556-561. 10.1007/s00535-009-0037-7, 19363643.
7. Cui L, Zhou H, Zhao H, Zhou Y, Xu R, Xu X, Zheng L, Xue Z, Xia W, Zhang B. MicroRNA-99a induces G1-phase cell cycle arrest and suppresses tumorigenicity in renal cell carcinoma. BMC Cancer 2012, 12(1):546. 10.1186/1471-2407-12-546, 3518250, 23173671.
8. Wulfken LM, Moritz R, Ohlmann C, Holdenrieder S, Jung V, Becker F, Herrmann E, Walgenbach-Brünagel G, von Ruecker A, Müller SC. MicroRNAs in renal cell carcinoma: diagnostic implications of serum miR-1233 levels. PLoS One 2011, 6(9):e25787. 10.1371/journal.pone.0025787, 3184173, 21984948.
9. Garofalo M, Croce CM. microRNAs: master regulators as potential therapeutics in cancer. Annu Rev Pharmacol Toxicol 2011, 51:25-43. 10.1146/annurev-pharmtox-010510-100517, 20809797.
10. Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, Schmandt R, Urbauer D, Pennacchio LA, Cheng J-F, Nick AM. Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med 2008, 359(25):2641-2650. 10.1056/NEJMoa0803785, 2710981, 19092150.
11. Karube Y, Tanaka H, Osada H, Tomida S, Tatematsu Y, Yanagisawa K, Yatabe Y, Takamizawa J, Miyoshi S, Mitsudomi T. Reduced expression of Dicer associated with poor prognosis in lung cancer patients. Cancer Sci 2005, 96(2):111-115. 10.1111/j.1349-7006.2005.00015.x, 15723655.
12. W-n W, Chen Y, Hu T-H. The regulatory mechanism of CCR7 gene expression and its involvement in the metastasis and progression of gastric cancer. Tumor Biol 2013, 34(3):1865-1871.
13. Noh H, Hong S, Dong Z, Pan ZK, Jing Q, Huang S. Impaired microRNA processing facilitates breast cancer cell invasion by upregulating urokinase-type plasminogen activator expression. Genes Cancer 2011, 2(2):140-150. 10.1177/1947601911408888, 3111246, 21779487.
14. Ambros V, Bartel B, Bartel DP, Burge CB, Carrington JC, Chen X, Dreyfuss G, Eddy SR, Griffiths-Jones S, Marshall M, Matzke M, Ruvkun G, Tuschl T. A uniform system for microRNA annotation. RNA (New York, NY) 2003, 9(3):277-279.
15. Dweep H, Sticht C, Pandey P, Gretz N. miRWalk-database: prediction of possible miRNA binding sites by " walking" the genes of three genomes. J Biomed Inform 2011, 44(5):839-847. 10.1016/j.jbi.2011.05.002, 21605702.
16. Dweep H, Sticht C, Kharkar A, Pandey P, Gretz N. Parallel analysis of mRNA and microRNA microarray profiles to explore functional regulatory patterns in polycystic kidney disease: using PKD/Mhm rat model. PLoS One 2013, 8(1):e53780. 10.1371/journal.pone.0053780, 3542345, 23326503.
17. Felekkis K, Voskarides K, Dweep H, Sticht C, Gretz N, Deltas C. Increased number of microRNA target sites in genes encoded in CNV regions. Evidence for an evolutionary genomic interaction. Mol Biol Evol 2011, 28(9):2421-2424. 10.1093/molbev/msr078, 21441354.
18. Papagregoriou G, Erguler K, Dweep H, Voskarides K, Koupepidou P, Athanasiou Y, Pierides A, Gretz N, Felekkis KN, Deltas C. A miR-1207-5p binding site polymorphism abolishes regulation of HBEGF and is associated with disease severity in CFHR5 nephropathy. PLoS One 2012, 7(2):e31021. 10.1371/journal.pone.0031021, 3271095, 22319602.
19. Mogyorósi A, Ziyadeh FN. What is the role of decorin in diabetic kidney disease?. Nephrol Dial Transpl 1999, 14(5):1078-1081.
20. Kumar MS, Lu J, Mercer KL, Golub TR, Jacks T. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet 2007, 39(5):673-677. 10.1038/ng2003, 17401365.
21. Han L, Zhang A, Zhou X, Xu P, Wang G-X, Pu P-Y, Kang C-S. Downregulation of Dicer enhances tumor cell proliferation and invasion. Int J Oncol 2010, 37(2):299.
22. Marin-Kuan M, Nestler S, Verguet C, Bezencon C, Piguet D, Mansourian R, Holzwarth J, Grigorov M, Delatour T, Mantle P. A toxicogenomics approach to identify new plausible epigenetic mechanisms of ochratoxin a carcinogenicity in rat. Toxicol Sci 2006, 89(1):120-134.
23. Mally A, Voelkel W, Amberg A, Kurz M, Wanek P, Eder E, Hard G, Dekant W. Functional, biochemical, and pathological effects of repeated oral administration of ochratoxin A to rats. Chem Res Toxicol 2005, 18(8):1242-1252. 10.1021/tx049651p, 16097797.
24. Hammond SM. Dicing and slicing: the core machinery of the RNA interference pathway. FEBS Lett 2005, 579(26):5822-5829. 10.1016/j.febslet.2005.08.079, 16214139.
25. Hutvagner G, McLachlan J, Pasquinelli AE, Bálint T, Tuschl T, Zamore PD. A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA. Sci Signal 2001, 293(5531):834.
26. Wang Y, Medvid R, Melton C, Jaenisch R, Blelloch R. DGCR8 is essential for microRNA biogenesis and silencing of embryonic stem cell self-renewal. Nat Genet 2007, 39(3):380-385. 10.1038/ng1969, 3008549, 17259983.
27. Gekle M, Schwerdt G, Freudinger R, Mildenberger S, Wilflingseder D, Pollack V, Dander M, Schramek H. Ochratoxin A induces JNK activation and apoptosis in MDCK-C7 cells at nanomolar concentrations. J Pharmacol Exp Ther 2000, 293(3):837-844.
28. Kumar R, Alam S, Chaudhari BP, Dwivedi PD, Jain SK, Ansari KM, Das M. Ochratoxin A-induced cell proliferation and tumor promotion in mouse skin by activating the expression of cyclin-D1 and cyclooxygenase-2 through nuclear factor-kappa B and activator protein-1. Carcinogenesis 2013, 34(3):647-657. 10.1093/carcin/bgs368, 23172667.
29. Patron JP, Fendler A, Bild M, Jung U, Müller H, Arntzen M, Piso C, Stephan C, Thiede B, Mollenkopf H-J. MiR-133b targets antiapoptotic genes and enhances death receptor-induced apoptosis. PLoS One 2012, 7(4):e35345. 10.1371/journal.pone.0035345, 3332114, 22532850.
30. Rached E, Hard GC, Blumbach K, Weber K, Draheim R, Lutz WK, Özden S, Steger U, Dekant W, Mally A. Ochratoxin A: 13-week oral toxicity and cell proliferation in male F344/N rats. Toxicol Sci 2007, 97(2):288-298. 10.1093/toxsci/kfm042, 17344223.
31. Kawakami K, Enokida H, Chiyomaru T, Tatarano S, Yoshino H, Kagara I, Gotanda T, Tachiwada T, Nishiyama K, Nohata N. The functional significance of miR-1 and miR-133a in renal cell carcinoma. Eur J Cancer 2012, 48(6):827-836. 10.1016/j.ejca.2011.06.030, 21745735.
32. Yoshino H, Chiyomaru T, Enokida H, Kawakami K, Tatarano S, Nishiyama K, Nohata N, Seki N, Nakagawa M. The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer. Br J Cancer 2011, 104(5):808-818. 10.1038/bjc.2011.23, 3048214, 21304530.
33. Stachurska A, Ciesla M, Kozakowska M, Wolffram S, Boesch-Saadatmandi C, Rimbach G, Jozkowicz A, Dulak J, Loboda A. Cross-talk between microRNAs, nuclear factor E2-related factor 2, and heme oxygenase-1 in ochratoxin A-induced toxic effects in renal proximal tubular epithelial cells. Mol Nutr Food Res 2013, 57(3):504-515. 10.1002/mnfr.201200456, 23281030.
34. Slocum SL, Kensler TW. Nrf2: control of sensitivity to carcinogens. Arch Toxicol 2011, 85(4):273-284. 10.1007/s00204-011-0675-4, 21369766.
35. Wakabayashi N, Slocum SL, Skoko JJ, Shin S, Kensler TW. When NRF2 talks, who's listening?. Antioxid Redox Signal 2010, 13(11):1649-1663. 10.1089/ars.2010.3216, 2966480, 20367496.
36. Cavin C, Delatour T, Marin-Kuan M, Holzhäuser D, Higgins L, Bezencon C, Guignard G, Junod S, Richoz-Payot J, Gremaud E. Reduction in antioxidant defenses may contribute to ochratoxin A toxicity and carcinogenicity. Toxicol Sci 2007, 96(1):30-39.
37. van Jaarsveld MT, Helleman J, Boersma AW, van Kuijk PF, van Ijcken WF, Despierre E, Vergote I, Mathijssen RH, Berns EM, Verweij J, Pothof J, Wiemer EA. miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells. Oncogene 2013, 32(36):4284-4293. 10.1038/onc.2012.433, 23045278.
38. Peng X-L, Xu W-T, Wang Y, Huang K-L, Liang Z-H, Zhao W-W, Luo Y-B. Mycotoxin ochratoxin A-induced cell death and changes in oxidative metabolism of Arabidopsis thaliana. Plant Cell Rep 2010, 29(2):153-161. 10.1007/s00299-009-0808-x, 20039043.